Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are pleased to announce that today the University of Oxford MRC Brain Network Dynamics Unit joins the Nuffield Department of Clinical Neurosciences (NDCN) as a sixth division.

The MRC BNDU had its funding renewed earlier this year, and is developing its integrated approach to fundamental and translational neuroscience. NDCN as its new host department will be able to exploit existing collaborations with MRC BNDU researchers, as well as finding new ways to work together.

The MRC BNDU’s key strength is its focus on understanding and exploiting the moment-to-moment interactions between brain cells, particularly those involved in movement and memory. A deeper understanding of these circuits could help us develop interventions for when things go wrong in these brain mechanisms.

We in NDCN look forward to learning from the MRC BNDU’s exemplary approach to public engagement, staff development, data sharing and working with industry.

The Unit, led by Professor Peter Brown, will continue to have its main physical base next to the Department of Pharmacology on Mansfield Road. This will help to consolidate our foothold ‘down the hill’, first established by our Sleep and Circadian Neuroscience Institute, which is currently located in the Dunn School of Pathology.

Find out more at www.mrcbndu.ox.ac.uk/

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.